XML 39 R26.htm IDEA: XBRL DOCUMENT v3.25.1
Segment Information (Tables)
 3 Months Ended
Mar. 28, 2025
Segment Reporting [Abstract]  
Segment Results Detailed segment data for the three-month periods ended March 28, 2025 and March 29, 2024 is as follows ($ in millions):
BiotechnologyLife SciencesDiagnostics
Other(a)
Total
For the Three-Month Period Ended March 28, 2025:
Sales$1,612 $1,680 $2,449 $— $5,741 
Less:
Depreciation(34)(45)(100)(2)(181)
Amortization of intangible assets(213)(149)(48)— (410)
Other segment expenses(b)
(924)(1,285)(1,583)(84)(3,876)
Operating profit$441 $201 $718 $(86)$1,274 
For the Three-Month Period Ended March 29, 2024:
Sales$1,524 $1,745 $2,527 $— $5,796 
Less:
Depreciation(42)(38)(97)(2)(179)
Amortization of intangible assets(218)(141)(48)— (407)
Other segment expenses(b)
(939)(1,331)(1,552)(76)(3,898)
Operating profit$325 $235 $830 $(78)$1,312 
(a) Other consists of unallocated corporate costs and other costs not considered part of management’s evaluation of reportable segment operating performance.
(b) Other segment expenses for each reportable segment include cost of sales, selling, general and administrative (“SG&A”) expenses, research and development (“R&D”) expenses, excluding in each case depreciation and amortization of intangible assets. Included within these categories of expenses are overhead expenses, stock compensation expense, restructuring charges and allocated corporate expenses.
The following table presents identifiable assets as of March 28, 2025 and December 31, 2024 ($ in millions):
March 28, 2025December 31, 2024
Identifiable assets:
Biotechnology$36,121 $34,605 
Life Sciences23,396 23,211 
Diagnostics14,291 14,204 
Other5,308 5,522 
Total$79,116 $77,542 
The following table presents capital expenditures for the three-month periods ended March 28, 2025 and March 29, 2024 ($ in millions):
Three-Month Period Ended
March 28, 2025March 29, 2024
Capital expenditures:
Biotechnology$81 $102 
Life Sciences48 60 
Diagnostics115 127 
Other1 2 
Total$245 $291